Vaccines against human carcinomas: strategies to improve antitumor immune responses.
about
Cancer Dormancy: A Regulatory Role for Endogenous Immunity in Establishing and Maintaining the Tumor Dormant StateThe Evolving Role of Immune Checkpoint Inhibitors in Cancer TreatmentEnantiospecific adjuvant activity of cationic lipid DOTAP in cancer vaccine.Prognostic impact of peritumoral lymphocyte infiltration in soft tissue sarcomasCombinatorial contextualization of peptidic epitopes for enhanced cellular immunity.The consequence of immune suppressive cells in the use of therapeutic cancer vaccines and their importance in immune monitoringVaccines targeting the neovasculature of tumorsSipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments.Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors.Extended evaluation of a phase 1/2 trial on dosing, safety, immunogenicity, and overall survival after immunizations with an advanced-generation Ad5 [E1-, E2b-]-CEA(6D) vaccine in late-stage colorectal cancerAdjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination.A Comprehensive Preclinical Model Evaluating the Recombinant PRAME Antigen Combined With the AS15 Immunostimulant to Fight Against PRAME-expressing TumorsStrategies to target molecules that control the acquisition of a mesenchymal-like phenotype by carcinoma cells.Cancer vaccines: Looking to the future.Novel adenoviral vector induces T-cell responses despite anti-adenoviral neutralizing antibodies in colorectal cancer patientsCancer vaccines. Any future?Tumor evasion from T cell surveillance.The evolving role of immunotherapy in prostate cancer.Can immuno-oncology offer a truly pan-tumour approach to therapy?Could mycobacterial Hsp70-containing fusion protein lead the way to an affordable therapeutic cancer vaccine?Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy.Clinically feasible approaches to potentiating cancer cell-based immunotherapies.Development of Cancer Vaccines Targeting Brachyury, a Transcription Factor Associated with Tumor Epithelial-Mesenchymal Transition.Breast cancer vaccines delivered by dendritic cell-targeted lentivectors induce potent antitumor immune responses and protect mice from mammary tumor growth.Endogenous immunity at the forefront of tumor dormancy.
P2860
Q26782573-677D2B4F-D2EC-4632-8639-07FEFA61F83CQ27022789-26497CA2-0CEA-436B-B80E-ACFC384BBD60Q33912706-6A77882D-DFE7-48D6-AD94-09B232F419D2Q34178633-483A7FFF-AF3C-422C-B28C-4D3DA8BD6B52Q34400527-E9155B4C-33EB-4A66-B314-560C472BC1EBQ34557531-4ECE8D5A-1483-464E-8A89-861F86388D00Q34704905-94FF4214-89E5-4830-995A-B715A56D4B01Q35128716-1AA60D4B-BEB0-4A55-95B6-D3AD4EFF60E3Q35580479-916DAEF9-C794-47E4-AA92-511DD26ABE8AQ35864700-0C461849-1E1B-4B75-B205-5E724F942319Q35886450-2F0F77D0-FA19-4680-B2CF-525D29C771AEQ36322371-E11932AA-B8C1-40F9-9507-2F1257650435Q36430004-24FEB41D-F8E5-4EF9-8922-6A1DED67C545Q36866158-7768DF80-8EC4-4BB4-820B-B61D01DE1754Q37068071-1F88E04D-BC9A-4CC0-893C-282D15E53DEEQ37885282-BDAA8EC2-A2F5-41E7-B3D5-BFDB95F4A255Q37970674-0F578630-0062-4A36-BF5E-C239744C05BDQ38037488-E513D059-6C70-4298-865D-BEDEC09DEDBBQ38037493-28D1E80F-CAF9-4872-9E6D-8E618FAC298CQ38286381-346A58FD-2902-4F60-AB02-3DBFA5D07EC2Q38416306-038AA2D8-8BC8-4E5D-9671-C6EBB356FA72Q38453610-E81D993B-6BE1-44B0-8683-F705091CA2BAQ39142273-2BACBE1E-3A14-47F1-9237-2C9E98F253D9Q41936513-5CF23A06-D39E-4377-9844-BEE3D81714D9Q42358566-D50365DA-D3B9-43D0-8455-9C65E65EDB71
P2860
Vaccines against human carcinomas: strategies to improve antitumor immune responses.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Vaccines against human carcinomas: strategies to improve antitumor immune responses.
@ast
Vaccines against human carcinomas: strategies to improve antitumor immune responses.
@en
type
label
Vaccines against human carcinomas: strategies to improve antitumor immune responses.
@ast
Vaccines against human carcinomas: strategies to improve antitumor immune responses.
@en
prefLabel
Vaccines against human carcinomas: strategies to improve antitumor immune responses.
@ast
Vaccines against human carcinomas: strategies to improve antitumor immune responses.
@en
P2860
P356
P1476
Vaccines against human carcinomas: strategies to improve antitumor immune responses.
@en
P2093
Claudia Palena
Jeffrey Schlom
P2860
P304
P356
10.1155/2010/380697
P577
2010-03-16T00:00:00Z